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Abstract
Neuropilins (NRP) are cell surface receptors for VEGF and SEMA3 family members. The role of
NRP in neurons and endothelial cells has been investigated, but the expression and role of NRP in
epithelial cells is much less clear. Herein, the expression and localization of neuropilin 1 (NRP1)
was investigated in human and mouse skin and squamous cell carcinomas (SCC). Results
indicated that NRP1 mRNA and protein was expressed in the suprabasal epithelial layers of skin
sections. NRP1 staining did not overlap with that of keratin 14 (K14) or proliferating cell nuclear
antigen, but did colocalize with staining for keratin 1, indicating that differentiated keratinocytes
express NRP1. Similar to the expression of NRP1, VEGF-A was expressed in suprabasal epithelial
cells, whereas Nrp2 and VEGFR2 were not detectable in the epidermis. The expression of NRP1
correlated with a high degree of differentiation in human SCC specimens, human SCC xenografts,
and mouse K14-HPV16 transgenic SCC. UVB irradiation of mouse skin induced Nrp1
upregulation. In vitro, Nrp1 was upregulated in primary keratinocytes in response to
differentiating media or EGF-family growth factors. In conclusion, the expression of NRP1 is
regulated in the skin and is selectively produced in differentiated epithelial cells. NRP1 may
function as a reservoir to sequester VEGF ligand within the epithelial compartment, thereby
modulating its bioactivity.
Keywords
squamous cell carcinoma; skin cancer; angiogenesis; differentiation; epithelium; neuropilin;
semaphorin
Neuropilins (NRP, human; Nrp, mouse) are type I transmembrane receptors for two distinct
ligand families—the vascular endothelial growth factor (VEGF) family of angiogenic
molecules and the class 3 semaphorin (SEMA3) family of guidance proteins (1, 2). The two
neuropilin genes, NRP1 and NRP2, are located on different chromosomes (3). Both NRP
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tproteins are similarly sized and have analogous domain structures (4, 5). The two NRP
receptors share some ligands including VEGF-A (hereafter called VEGF), but differ in their
specificity for other VEGF family members (6-8); for example, NRP1 binds placenta growth
factor 2 (PlGF2) (9), whereas NRP2 binds VEGF-C and VEGF-D (10).
NRPs were first characterized as neuronal guidance receptors (11, 12), and their role in the
vasculature has also been widely studied. Endothelial cells express NRP with some degree
of specificity during development such that arteries express Nrp1 and veins and lymphatics
express Nrp2 (13-15). In contrast, the expression, regulation and function of NRPs in
epithelial cells are unclear (16). Previously, we reported that human skin expresses full-
length NRP1 but not soluble NRP1 (sNRP1) (17). Additionally, we have demonstrated the
upregulation of NRP1 in keratinocytes by growth factors such as epidermal growth factor
(EGF), and down regulation by transcription factors such as the neuron restrictive silencer
factor (NRSF) (18).
Genetically-engineered mice lacking Nrp1 (knockout) are embryonic lethal at E12.5-13.5
(19). Tissue-specific deletion of Nrp1 in epithelial cells, achieved by crossing K14-cre mice
and Nrp1-floxed mice, yield mice that are viable and show no obvious phenotype (20). Yet,
mice lacking Nrp1 in the epidermis are more sensitive to UVB irradiation and displayed
increased apoptosis following irradiation (20). Using mice overexpressing sNRP1 in the
epidermis (K14-sNRP1), we demonstrated that sNRP1 could diffuse through the basement
membrane of the epidermal/dermal junction and inhibit dermal blood vessels and vascular
permeability (21).
Within the skin epithelium, the VEGF protein is localized in suprabasal layers— farthest
from dermal vessels (22). The VEGF ligand has been shown to be upregulated in the
epidermis in association with ischemia, wound healing or hyperplasia (23, 24). Moreover,
VEGF is highly expressed by invasive and metastatic human squamous cell carcinomas
(SCC) (25), yet its expression also correlates with the degree of differentiation in cutaneous
human SCC (26). In fact, overexpression of VEGF by lowgrade SCC cells (SCC13)
increased their growth rate and invasiveness (27). In order to clarify some of these findings
and further our understanding of the potential function of VEGF in the epithelium, we
interrogated the expression profile of neuropilin 1 in the skin and investigated its regulation
both in vitro and in vivo under normal physiological conditions as well as in SCC models.
Materials and Methods
Cell culture
A431 human epidermoid SCC cells, originally isolated from an 85-year old woman (28),
were purchased from American Type Culture Collection (ATCC). DJM1 cells, originally
isolated from a 54-year-old woman with metastatic SCC (29), were obtained from Dr.
Misuzu Seo (Kyoto Sangyo University, Japan). SCC13 cells, originally isolated from a 56-
year-old female with facial SCC that was previously treated with radiation (30), were
obtained from Dr. James Rheinwald (Harvard Medical School). HaCat, spontaneously
immortalized human keratinocytes (31), and all human SCC lines were cultured in minimal
essential media (MEM, Life Technologies) supplemented with 10% fetal bovine serum
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t(FBS) and 1% glutamine-penstrep (GPS, Life Technologies). HaCat were incubated with
EGF (10 ng/ml) for indicated times. Primary normal human umbilical vein endothelial cells
(HUVEC) were purchased from Lonza and cultured in EGM2 (Lonza). Porcine aortic
endothelial (PAE) cells overexpressing human NRP1 or NRP2 were obtained from Dr.
Michael Klagsbrun (Harvard Medical School) and cultured in Ham's F12 media (Life
Technologies) supplemented with 10% FBS and 1% GPS. Mouse hemangioendothelioma
EOMA cells (32) were purchased from ATCC and maintained in high glucose DMEM (Life
Technologies) with 10% FBS and 1% GPS.
Animal studies
Tumor Inoculation—Adult (8-wk) female Balb/c Nude (nu/nu) mice were purchased
from Massachusetts General Hospital. Human SCC cells (1 × 106) were injected
subdermally (33) on the right dorsal flank. Thirty days later, mice were euthanized; tumors
were removed, fixed in formalin, and embedded in paraffin.
Ultraviolet B (UVB) Irradiation—Adult (8-wk) female C57Bl/6 mice were purchased
from Charles River Laboratories and exposed to a single 15kJ/m2 dose of UVB irradiation
as previously described (34). Mice were euthanized at various time points; and their exposed
ears were resected, fixed in formalin, and embedded in paraffin. Agematched, unirradiated
mice served as normal controls.
Transgenic/knockin mice—Ears from adult (3-month) heterozygous VEGFR2+/LacZ
(also called Flk1+/LacZ) mice (35) were resected under anesthesia, frozen in OCT compound,
and stained with X-gal reagent to detect β-galactosidase activity. Heterozygous Nrp2+/LacZ
mice (36, 37) were euthanized at P1 or P42 (6 wk). Dorsal skin was shaved, removed, frozen
in OCT compound, and stained with X-gal reagent. Transgenic mice expressing the human
papillomavirus type 16 early region genes under the control of the keratin 14 promoter
(K14-HPV16 mice) (38, 39) were euthanized at various time points during their disease
progression from hyperplastic to dysplastic to squamous cell carcinoma. Ears were resected,
fixed in formalin, and embedded in paraffin.
Keratinocyte isolation
Adult lactating female Balb/c mice with new litters were purchased from Charles River
Laboratories. P3 pups were euthanized, and skin tissue was used for primary epidermal cell
isolation as described (38). Cells (1′MK) were maintained in MEM with 8% calcium-
chelated FBS and cultured in low calcium (0.05 mM CaCl2) media or differentiated in high
calcium (0.12 mM CaCl2) media or retinoic acid (3 mM) media for various time points (40).
Alternately, cells were incubated for various times in media containing HB-EGF (10 ng/ml)
or SEMA3A (640 ng/ml).
Northern blot analysis
Cells were incubated with growth factors or differentiating agents and cellular mRNA
purified using the FastTrack mRNA isolation kit (Life Technologies). mRNA was separated
on formaldehyde/agarose gels, transferred to nylon membranes and hybridized with 32P-
labeled cDNA-probes corresponding to 838-bp mouse NRP1 b domain generated with
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(21) or 950-bp human NRP1 b domain generated with primers
5′GAAGATTTCAAATGTATGGAAG and 3′GGCTTCCACTTCACAGCCCAG (17).
Probes were labeled with Rediprime II, random primed synthesis kit (GE Healthcare). Blots
were washed and exposed to Kodak film. Blots were stripped and hybridized with a β-actin
probe to normalize RNA loading.
Western blot analysis
Cells were lysed in RIPA buffer (Boston Bioproducts) and complete protease inhibitor
cocktail (Roche). Proteins in either reducing or non-reducing sample buffer were run on
7.5% SDS-PAGE and transferred to nitrocellulose. Membranes were blocked with nonfat
milk and incubated with rabbit polyclonal anti-human NRP1 (44-2) (recognizing amino
acids DDSKRKAKSFEGNNNYD in the b2 domain; not commercial) (18) or goat anti-rat/
mouse Nrp1 (R&D Systems). Membranes were incubated with HRP-linked secondary
antibodies, donkey anti-rabbit (GE Healthcare) or donkey anti-goat (R&D Systems), and
detected with Western Lightning Plus ECL (PerkinElmer). Blots were stripped with Reblot
Plus (Millipore) and re-probed with rabbit anti-GAPDH (Abcam) to normalize for protein
loading.
VEGF cross-linking
HaCat or HUVEC were pretreated with HB-EGF (10 ng/ml) for 24 hrs to upregulate NRP1.
VEGF165 (carrier-free, R&D Systems) was radioiodinated using IODO-BEADS as
previously described (1). Cells were incubated on ice for 2 hr in the presence of I125-
VEGF165 and heparin (1 mg/ml) or SEMA3A and cross-linked with disuccinimidyl suberate
(DSS, Pierce). Cross-linked complexes were resolved by 6% SDS-PAGE, and gels were
exposed to X-ray films.
Immunocytochemistry (ICC)
PAE cells or primary mouse keratinocytes were grown on glass slides and fixed with 4%
paraformaldehyde in PBS. Endogenous peroxidase was quenched with 3% H2O2 in
methanol, proteins blocked with TNB (PerkinElmer), and incubated with either rabbit anti-
human NRP1 (44-2; not commercial) or rabbit anti-mouse keratin 1 (AF109; Covance).
Sections were incubated with biotinylated goat anti-rabbit (Vector), Vectastain Elite HRP-
linked avidin (Vector), and diaminobenzidine (DAB, Vector). Cells were counterstained in
hematoxylin (H) (Sigma-Aldrich) and mounted with Permount (Fisher Scientific).
Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded sections were deparaffinized in xylene and rehydrated
through a graded series of alcohols to water. Antigen retrieval included proteinase K (20
μg/ml) for CD31 and mouse Nrp1 and heat-induced epitope retrieval for PCNA. Staining
with the other antibodies did not require antigen retrieval.
Endogenous peroxidase was inhibited with 3% H2O2 in methanol, and proteins were
blocked in TNB. Sections were incubated in primary antibodies overnight at 4°C including
rabbit anti-human NRP1 44-2 (not commercial), rabbit monoclonal anti-mouse Nrp1 (clone
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tEPR3113; detects C terminus and not sNrp1; Epitomics), monoclonal anti-PCNA (clone
PC10; Dako), rabbit anti-human keratin 1 (AF87; Covance), rabbit anti-human keratin 14
(AF64; Covance), and monoclonal rat anti-mouse CD31 (clone MEC13.3; BD Pharmingen).
Sections were incubated in secondary antibodies including HRP-conjugated rat anti-mouse
IgG2a (Serotec), biotinylated goat anti-rabbit (Vector), biotinylated goat anti-rat (mouse
absorbed; Vector), Vectastain Elite HRP-linked avidin, and DAB. Cells were counterstained
with hematoxylin and mounted with Permount.
Human SCC array and scoring
Human skin cancer tissue microarray slides (A216) containing 50 cases/2 spots each were
purchased from AccuMax Array. Sections were stained for human NRP1 as described above
and then scored by a pathologist. Staining was ranked according to area of staining (1-3:1 =
1-10%, 2 = 11 -50%, 3 = >50%) and intensity of staining (1-3, with 3 for greatest intensity
of staining). Staining Index was calculated as area × intensity (9 = highest, 0 = lowest).
X-gal staining
For detection of β-galactosidase activity, cryosections from VEGFLacZ, VEGFR2+/LacZ or
Nrp2+/LacZ mice were fixed in methanol and incubated (37°C) in X-gal [1 mg/ml X-gal (5-
bromo-4-chloro-3-indolyl-b-D-galactopyranoside) in DMSO; 5 mM K3Fe(CN)6; 5Mm
K4Fe(CN)6; 2 mM MgCl2 in PBS; pH 6.5]. Sections were counterstained with eosin (E)
(Sigma) and mounted with Permount.
In situ hybridization
Sections were de-waxed, rehydrated, and digested with proteinase k; then, post-fixed,
dehydrated, and air-dried. Anti-sense human NRP1-specific riboprobe and sense probe were
synthesized from 750-bp 3′UTR-derived cDNA using a digoxigenin RNA-labeling kit
(Roche) as previously described (17, 41). Anti-sense mouse Nrp1-specific riboprobe and
sense probe were created similarly from a 500-bp cDNA (41). Probes were hybridized and
washed in SSC. Alkaline phosphatase-labeled anti-digoxigenin and BM Purple (Roche)
were used to visualize the reaction.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total mRNA was isolated from primary mouse keratinocytes (1′MK) or EOMA cells using
RNeasy mini kit (Qiagen) with RT reaction and PCR performed as previously described (42,
43). The following primer pairs were used: mouse NRP1 a domain (404bp) F5′-GGC TGC
CGT TGC TGT GCG-3′ and R5′-ATA GCG GAT GGA AAA CCC-3′; VEGF (amplifying
all known isoforms of mouse VEGF-A) F5′-GGG TGC ACT GGA CCC TGG CTT TAC-3′
and R5′-CCT GGC TCA CCG CCT TGG CTT GTC-3′; VEGFR-1 (625 bp) F5′-GGC TCA
GGG TCG AAG TTA AAA GTG CCT-3′ and R5′-TAG GAT TGT ATT GGT CTG CCG
ATG GGT-3′; VEGFR-2 (408 bp) F5′-CTC TGT GGG TTT GCC TGG CGA TTT TCT-3′
and R5′-GCG GAT CAC CAC AGT TTT GTT CTT GTT-3′; GAPDH F5′-ACC CCT TCA
TTG ACC TCA ACT-3′ and R5′-CCACCA CCCTGTTGCTGTAG-3′.
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NRP1 expression in normal skin
We previously described high NRP1 expression in human skin (17, 18). Herein, we
examined NRP1 protein localization in human paraffin skin sections at a higher resolution
using IHC. NRP1 protein was highly expressed in all suprabasal epithelial cells as well as in
dermal endothelial cells (Figure 1A, brown color). The negative control, secondary antibody
alone, showed no specific staining in the skin (Figure 1B). The NRP1 antibody was specific
to NRP1 and did not react with human NRP2 as shown by western blot or ICC analyses
(Figure S1A-B). NRP1 mRNA was also found exclusively in suprabasal epithelial cells and
dermal blood vessels as demonstrated by in situ hybridization (Figure 1C-D, purple color).
Double IHC with antibodies to human NRP1 and proliferating cell nuclear antigen (PCNA)
(Figure 1E) or NRP1 and K14 (Figure 1F) demonstrated that basal cells in the epidermis did
not express NRP1.
NRP1 in human SCC specimens
We next examined the expression and localization of NRP1 protein in human cutaneous
SCC specimens. Human SCC tissue microarrays (#A216) were stained by IHC for NRP1
(Figure 2A) and results were recorded by a staining index as described in the methods. Table
1 summarizes the differentiation status of the SCC specimens, NRP1 staining index, sex,
age, tumor stage, and tumor size. All cases were positive for NRP1, and representative
stainings of normal skin (NR), highly differentiated (HD), moderately differentiated (MD),
and poorly differentiated (PD) SCC are shown in Figure 2C. NRP1 staining index scores
ranged from 6-9 for HD samples, from 3-6 for MD samples, and from 2-3 for PD samples
(Table 1). Highly differentiated human SCC samples with surrounding normal cutaneous
tissues were also stained for NRP1 using IHC. NRP1 protein was upregulated in SCC tumor
tissue and also found in adjacent hyperplastic suprabasal epithelium (Figure 2B). Strong
NRP1 protein expression in SCC correlated with high differentiation status but did not
correlate with age, sex, size or tumor stage (Table 1, Figure 2 A-C).
NRP1 in human SCC xenografts
Three human SCC cell lines with varying differentiation status were injected subdermally in
nude mice, allowed to grow for one month, and resected. Paraffin sections of tumors were
stained by hematoxylin and eosin (H&E), and entire cross-sections were scanned and shown
in Figure S2A-C. SCC13 tumors are highly differentiated (Figure S2A), DJM1 tumors are
moderately differentiated (Figure S2B), and A431 tumors are poorly differentiated (Figure
S2C). Tumor sections were also stained by IHC to detect human NRP1 (Figure 3A-C), to
detect human K1 in differentiated SCC cells (Figure 3D-F), and to detect (human) K14 in all
human epithelial cells (Figure 3G-I). All tumors expressed K14. As expected, the majority
of SCC13 strongly expressed K1, confirming their high differentiation status (Figure 3D).
DJM1 expressed K1 in a heterogeneous pattern throughout the tumor (Figure 3E), whereas
A431 lacked K1 staining (Figure 3F). NRP1 staining paralleled that of K1 in all tumors;
NRP1 was high in SCC13, moderate in DJM1 and absent in A431 (Figure 3A-C). In the
SCC13 tumors, basal/proliferating cells (arrow) lacked NRP1 and K1 (Figures 3A and 3D,
respectively).
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Ears from adult K14-HPV16 mice were evaluated histologically at various stages including
hyperplastic (baseline) (Figure 4A, D, G), papillomatous and/or dysplastic (Figure 4B, E,
H), and at time points when SCC was observed (Figure 4C, F, I). Ear thickness dramatically
increased during tumor progression (compare width from central cartilage layer to outer
layer of epidermis, Figure 4 A vs. B). Thickness of the ear in tumor areas exceeded the field
of view (compare Figure 4 A vs. C). Nrp1 protein expression increased in dysplastic and
SCC samples as compared to baseline/control ears with Nrp1 localization remaining in
differentiated cells at all stages (Figure 4D-F). Microvessel density, as identified by CD31
IHC, also increased with tumor progression (Figure 4G-I), yet tumor vessels did not express
Nrp1.
Localization of VEGF and VEGF receptors using transgenic mice
Cryosections from VEGFR2+/LacZ mouse ears or Nrp2+/LacZ mouse skin were stained using
X-gal reagent to detect β -galactosidase activity. VEGFR2 expression (as detected by LacZ)
was detected only in dermal blood vessels and not in epithelial cells (Figure 5A-B). Nrp2
expression (also detected by LacZ) was observed in dermal vessels and in melanocytes of
hair follicles in P1 skin and in melanocytes and arrector pilli muscle (not shown) in adult
skin (Figure 5C-D); epidermal keratinocytes (arrowheads) lacked VEGFR2 and Nrp2.
Primary mouse keratinocytes (1′MK) were isolated from P3 mice and cultured in vitro.
Messenger RNA was isolated from the keratinocytes and mouse endothelioma cells
(EOMA) as a control, and RT-PCR was used to examine the levels of VEGF receptor
message (Figure S2D). 1′MK cells expressed only Nrp1 whereas EOMA expressed
VEGFR1, VEGFR2, and Nrp1. 1′MK also expressed VEGF mRNA, but to a lesser extent
than EOMA (Figure S2D).
Suprabasal epithelial cells have been shown by IHC and ISH to express VEGF-A (22, 23).
Since VEGF is a secreted protein that can bind heparan sulfate proteoglycans and may be
sequestered on the cell surface or in the extracellular matrix, IHC will not provide reliable
information about its source. Thus, we examined VEGF production in the skin using
transgenic mice in which the VEGF gene was tagged with LacZ with a nuclear translocation
signal (44). Blue nuclei (VEGF-producing cell) were detected primarily in suprabasal
keratinocytes and in hair follicles of mouse skin (Figure 5E).
Regulation of Nrp1 in vivo
UVB was previously shown to induce epidermal hyperplasia and dermal angiogenesis (23,
34). Mice lacking Nrp1 in the epithelium are more sensitive to the apoptotic effects of UVB
(20), therefore Nrp1 regulation was evaluated following UVB in vivo. Ear thickness
increased following UVB exposure (primarily on the outer ear surface) and the epidermis
increased from 1-2 cells to 6-8 cells thick (compare Figure 6 A vs. C). Levels of Nrp1
mRNA were increased in the suprabasal epithelial cells after just one day (not shown) but
were markedly increased by five to seven days post-UVB (Figure 6 E-F). There was little
Nrp1 staining in control ear sections at average chromogen incubation times (8 hrs) (Figure
6D), but Nrp1 expression was increased in outermost layers at longer incubation times (24
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thrs) (not shown). Due to the intense increase in Nrp1 expression following UVB, only short
exposure of ISH to chromogen was necessary.
Regulation of Nrp1 in vitro
To further investigate the regulation of Nrp1 expression in normal skin and epidermal cells,
we turned to an in vitro system. 1′MK were cultured under low calcium (non-differentiating)
or high calcium (differentiating) conditions with longer exposure of the cells to high calcium
media leading to a more dramatic change in cell shape (Figure 7A-C) and a higher level of
differentiation as evidence by expression of keratin 1 (K1) (Figure S3 A vs. E).
Differentiated cells expressed increased levels of Nrp1 protein (Figure 7D) as detected by
western blot following ConA-sepharose pull-down and mRNA (Figure 7E) as detected by
northern blot. Similarly, 1′MK cells, differentiated in media containing retinoic acid,
revealed increased levels of Nrp1 mRNA as the cells differentiated (Figure 7F). Treatment
of the cells with SEMA3A alone (data not shown) or in combination with high calcium
media did not affect the differentiation of 1′MK cells (Figure S3A-D).
To investigate the regulation of Nrp1 under proliferative conditions such as those associated
with UVB irradiation or with wound healing, 1′MK cells or human HaCat cells were treated
with HB-EGF or EGF. Additions of either growth factor led to the upregulation of NRP1 in
both mouse and human epithelial cells following treatment (Figure 7 G-H). The
functionality/binding ability of the NRP1 receptor protein was demonstrated by crosslinking
radioactive VEGF ligand. Specifically, the treatment of HaCat cells with HB-EGF led to the
upregulation of NRP1 which then bound more I125-VEGF165 as compared to untreated
control cells (Figure 7I, left panel). Unlabeled SEMA3A competed the binding of I125-
VEGF165 to both HaCat (Figure 7I, right panel) and to HUVEC (Figure S2E).
Discussion
Our previous studies indicated that NRP1 was expressed on epithelial cells at levels even
higher than on endothelial cells (17, 18). Yet, its expression pattern and regulation within the
epithelium was unknown. Herein, we demonstrate that NRP1 is found exclusively in
suprabasal (differentiated) epidermal cells in both mouse and human normal skin sections.
The NRP1 ligand, VEGF, was also expressed by differentiated cells (22, 23). Primary
keratinocytes cultured in normal growth media (low calcium), which does not support cell
differentiation, expressed barely detectable levels of Nrp1. Yet, switching the media to high
calcium concentrations or the addition of retinoic acid, which induced cell differentiation
(detected by the expression of keratin 1) was associated with the upregulation of Nrp1. The
expression of Nrp1 was not necessary for epidermal cell differentiation in vivo, since
epidermal-specific deletion of Nrp1 still express the differentiation markers keratin 10 and
loricrin (20).
Exposure of mouse skin to an acute dose of UVB irradiation (a typical physiological insult)
led to epithelial thickening (hyperplasia/proliferation) and increased expression of Nrp1.
Nrp1 localization was not altered in hyperplastic tissues where its expression remained
restricted to the suprabasal layers. UVB irradiation also increases VEGF expression in the
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tepidermis (23). Mice with epidermal-specific deletion of Nrp1 showed increased apoptosis
in response to UVB irradiation (20), suggesting that increased Nrp1 in the epidermis is
necessary for their survival. Exposure of cultured keratinocytes to EGF or HB-EGF, which
act as mitogens, also led to an upregulation of NRP1 in a time- and dose-dependent fashion.
This data is consistent with our previous reports (18, 45) and with those of others (46, 47).
Taken together, we conclude that NRP1 is generally expressed by differentiated, quiescent
epithelial cells; but that certain conditions (injury or growth) lead to the increased expression
of NRP1.
Since NRP1 is expressed by most epithelial cells (16), it was not surprising to find NRP1 in
the majority of carcinoma cells examined (7, 41). In the United States, skin carcinoma is the
most common form of cancer diagnosed (48). The yearly incidence of skin cancer is higher
than that of breast, prostate, lung and colon cancer combined (49). SCC a common form of
skin cancer, second only to basal cell carcinoma (BCC). Whereas BCC is rarely aggressive,
SCC can be invasive. In this study, we examined the expression of NRP1 in samples of
human SCC from tumors of various stages and sizes all on a single tissue microarray so as to
fairly compare NRP1 protein expression between samples. We found that levels of NRP1
were positively correlated with differentiation. In addition, using orthotopic xenograft
models of human SCC injected into mice, we discovered differing patterns of NRP1 protein
expression depending upon the tumor cell line used with NRP1 levels the strongest (or in the
greatest percentage of tumor cells) in SCC13. SCC13 are slow growing tumors with most of
the cells highly differentiated. In contrast, A431 SCC tumors are rapidly growing, contain
poorly differentiated tumor cells, and do not express NRP1; whereas, DJM1 tumors were
moderate in differentiation status and NRP1 levels.
Human and mouse skin differ in many characteristics including overall thickness,
compliance/ stiffness, and adhesion to underlying tissues (50). Epithelial carcinogenesis also
varies between human and mouse, but is similar in the step-wise transition from normal to
dysplasia to neoplasia. K14-HPV16 mice undergo transformation and tumor progression in
phases similar to human SCC disease progression with stages of hyperplasia and dysplasia
prior to squamous cell carcinoma (39). Using this model, we found that Nrp1 was expressed
in differentiated cells during all stages of progression and was upregulated during
hyperplastic and dysplastic phases. In human SCC, VEGF expression also correlated with
the degree of differentiation in cutaneous SCC (26). Taken together, these data, in both a
mouse model and human cells, indicate that differentiated, but not undifferentiated, tumor
cells express NRP1.
The tyrosine kinase VEGF receptors, VEGFR1, R2, and R3, are expressed by endothelial
cells of blood and lymphatic vessels and bind members of the VEGF ligand family. Most
VEGF functions are thought to result from VEGFR2 signaling (51). A few studies have
reported expression of VEGFR2 on cutaneous epithelial cells (52, 53), while others do not
find VEGFR2 expression in the epidermis (54, 55). We therefore chose to use knockin
VEGFR2+/LacZ mice to track the expression of VEGFR2/flk1 in the skin and avoid antibody
staining. Our results clearly demonstrate that epidermal cells do not express VEGFR2. In
addition, we did not see expression of VEGFR1 or VEGFR2 in cultured primary mouse
keratinocytes by RT-PCR, in agreement with our previous studies using HaCat keratinocytes
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t(18); others have found VEGFR1 on epidermal cells (55). NRP1, on the other hand, is
expressed in many epithelial cell types including the skin epidermis (16-18, 20, 21). Nrp2 is
not expressed by keratinocytes (Figure 5), but is upregulated in some carcinomas (7, 16, 41).
We previously published that HaCat keratinocytes do not express VEGFR1, R2, or R3 (18),
yet herein we demonstrate that they bind VEGF and express NRP1 (Figure 7).
In light of the fact that the NRP1 receptor does not have any intrinsic kinase activity, the
function of NRP1 in epithelial cells requires a more detailed analysis of keratinocytes and
their signal transduction pathways. That said, there are several potential roles for NRP1 in
the epidermis. First, NRP1 may directly signal via its Cterminal 3 amino acid (SEA) domain
that has been shown to bind to GIPC (56-58). Recent data suggests that PlGF signaling in
meduloblastoma requires this NRP1 C-terminal domain (59). Secondly, NRP1 may bind and
sequester VEGF protein for later use, for instance in wound healing. It is possible that
tumors with high NRP1 will bind more VEGF on their surface (as we show in Figure 7) and,
therefore, create a chemogradient of VEGF protein within the tumor to attract new blood
vessels into the tumor microenvironment. We have not shown this directly for SCC, but this
“reservoir effect” of Nrp1 for VEGF was demonstrated in prostate cancer cells transfected
with Nrp1 (60). Thirdly, there is also the possibility that NRP1 in the epithelium might
function as a receptor for other ligands such as SEMA3A, PlGF or HGF (9, 61, 62).
Consistent with this possibility, we previously showed that SEMA3A could inhibit
keratinocyte migration in vitro (18).
In conclusion, our data indicate that NRP1 is expressed in the normal epidermis and as such
is the sole VEGF receptor in these cells. NRP1 expression correlates with the level of
keratinocyte differentiation both in vitro and in vivo. NRP1 is regulated by physiologic
stimuli that cause hyperplasia such as UVB irradiation as well as pathologic stimuli that
cause dysplasia/neoplasia such as HPV. SCC (both human and mouse) express NRP1 in a
differentiation-dependent manner such that highly differentiated tumor cells express more
NRP1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. NRP1 mRNA and protein is expressed in suprabasal layers of the epidermis
(A) Paraffin sections of human skin were stained by IHC using anti-human NRP1 antibody.
Staining (brown color) was observed in suprabasal epithelium and dermal endothelium. (B)
Control sections, receiving all treatments except primary antibody, were negative for
staining. The epidermal-dermal junction is outlined with a dotted line. (C-D) Paraffin
sections of human skin were stained by ISH with probes to human NRP1 mRNA. Staining
(purple color) was observed in suprabasal epithelium and dermal endothelium. Basal
epithelium lacked staining. (E-F) Double IHC staining for human NRP1 (brown color) and
PCNA (nuclear blue color) (E) or K14 (blue color) (F). NRP1 expression was not detected
in dividing cells or basal cells. All scale bars = 100 μm.
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tFigure 2. NRP1 expression in human SCC patient samples correlates with degree of
differentiation
(A) Human skin cancer tissue microarray A216 was stained by IHC for NRP1 protein
expression. Illustrated is the scan of entire slide showing 102 sections/biopsies. Six samples
are marked with a line on the left and are shown at higher magnification below. (B) Scan of
entire section of highly differentiated human SCC sample stained by IHC for NRP1. Tumor
shows high expression of NRP1 (brown color). (C) Selected samples from microarray in A
demonstrate high NRP1 expression in normal (NR) epidermis and highly differentiated
(HD) SCC samples, medium NRP1 expression in moderately differentiated (MD) samples,
and the lack of NRP1 expression in poorly differentiated (PD) samples. Scale bar = 200 μm.
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tFigure 3. Differentiated cells of human SCC xenografts in mice express the highest levels of
NRP1
Three human SCC cell lines were grown in nude mice: welldifferentiated SCC13 (A, D, G),
moderately differentiated DJM1 (B, E, H), and poorly differentiated A431 (C, F, I). Paraffin
sections of tumors were stained by IHC for human NRP1 (A-C), human K1 (D-F), and
human K14 (G-I). Note that human NRP1 antibodies do not stain mouse blood vessels.
NRP1 is absent from poorly differentiated human SCC cells (arrows in A, D). Scale bar =
100 μm.
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tFigure 4. Nrp1 is expressed in normal mouse epithelium and murine SCC
Transgenic K14-HPV16 mice develop spontaneous and progressive dysplasia and SCC.
Paraffin sections of ears from K14-HPV16 mice were obtained before overt disease
(normal) (A, D, G), from dysplastic ears (B, E, H), or from SCC tumors (C, F, I). Sections
were stained with H&E (A-C) or immunostained for mouse Nrp1 (brown color) (D-F) or
mouse CD31 (brown color) (G-I). Nrp1 expression increased in dysplastic lesions (E) and
was expressed in differentiated areas of SCC (F). Microvessel density progressively
increased from normal/hyperplastic epidermis (G) to dysplasia (H) to SCC (I). Some
sections (D-I) were counterstained with hematoxylin (blue color). All images were taken at
200× magnification; scale bars = 100 μm. Notice the ears increase dramatically in thickness.
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tFigure 5. Murine keratinocytes express VEGF but not VEGFR2 or Nrp2
Cryosections of VEGFR2+/LacZ mouse ears (A, B), Nrp2+/LacZ mouse skin (C, D) and
VEGFLacZ mouse skin (E) were stained with X-gal reagent to detect β-galactosidase. (A-B)
Blue staining shows VEGFR2 expression in dermal blood vessels but not in epithelial cells
(arrow heads). (C-D) Blue staining demonstrates Nrp2 expression in melanocytes of hair
follicles and some dermal blood vessels, but not in the epidermis (arrrow heads) of P1
mouse skin (C) or P42 mouse skin (D). Scale bars in A-D = 100 μm. (E) Blue staining nuclei
denote cells producing VEGF (arrows). Keratinocytes in suprabasal layers and hair follicles
make VEGF. Sections were counterstained with Eosin (pink color). Scale bar in E = 50 μm.
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tFigure 6. Nrp1 mRNA expression increased following UVB irradiation
Paraffin sections of mouse ears from normal, non-irradiated (control) (A, D) or UVB
irradiated mice (B, C, E, F). Sections were stained with H&E (A-C) or by ISH with probes
to mouse Nrp1 mRNA (purple color). Nrp1 expression was increased in epidermal cells and
dermal vessels after UVB irradiation (E, F). Nrp1 mRNA expression was seen only in
suprabasal cells of the epidermis. There was low Nrp1 expression in normal ears at short
chromogen incubations (D) but expression was detectable when incubation time was
increased (not shown). All images were taken at 200× magnification; scale bars = 100 μm.
Notice the ears increase dramatically in thickness.
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tFigure 7. NRP1 expression is regulated by differentiation and growth factors in vitro
(A-C) Primary mouse keratinocytes were isolated and cultured from P3 Balb/c mice. Cells
were grown in (A) low calcium growth media or differentiating high calcium media for (B)
one to (C) three days. Phase contrast microscopy demonstrated changes in cell shape and
morphology. (D) Western blot of protein lysates from primary mouse keratinocytes cultured
in low (lo = 0.05mM) or high (hi = 0.12mM) calcium media. Nrp1 protein is upregulated in
cells grown in the differentiating media. (E-F) Northern blot of mRNA from primary mouse
keratinocytes cultured in (E) high calcium media or (F) retinoic acid (RA) for various time
points. Nrp1 was induced in cells grown for one day in high calcium media or four days in
RA. (G-H) Northern blot of mRNA from primary mouse keratinocytes (G) or human Hacat
cells (H) incubated for various times in growth factor. Addition of HB-EGF or EGF
upregulated NRP1 expression in keratinocytes. (I) I125-VEGF165 crosslinking to NRP1 on
Hacat cells increased after pretreatment in HBEGF (left panel). I125-VEGF165 crosslinking
to NRP1 on Hacat cells was competed in the presence of excess SEMA3A protein (right
panel). Arrowheads point to the crosslinked complex of NRP1/VEGF.
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